-
-
Overview
-
Dipeptidyl peptidase IV (DPP-IV) inhibitor.
Vildagliptin, also known as LAF237, is a potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin inhibits the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) by DPP-IV, allowing GLP-1 and GIP to potentiate the secretion of insulin and suppress glucagon release in the pancreas. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity in type 2 diabetes.
Please contact us for availability.Please contact us at for specific academic pricing.
-
- Properties
-
Overview